Enterprise Value

93.6M

Cash

172.3M

Avg Qtr Burn

-22.99M

Short % of Float

33.82%

Insider Ownership

7.43%

Institutional Own.

77.18%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PRT811 (PRMT5 inhibitor) Details
Glioblastoma, Cancer, primary central nervous system lymphomas

Phase 1

Data readout

PRT543 (PRMT5 inhibitor) Details
Solid tumor/s, Myelodysplastic syndrome, Myelofibrosis, Cancer

Phase 1

Data readout

PRT1419 (MCL1 inhibitor) Details
Myelodysplastic syndrome, Non-Hodgkin lymphoma, Acute myeloid leukemia, Multiple myeloma

Phase 1

Data readout

PRT2527 (CDK9 inhibitor) Details
Myelodysplastic syndrome, Non-Hodgkin lymphoma, Acute myeloid leukemia, Multiple myeloma

Phase 1

Data readout

PRT3645 (CDK4/6 inhibitor) Details
Glioblastoma, Head and neck cancer, Non-small cell lung carcinoma, Breast cancer

Phase 1

Data readout